Jasmonates are potent lipid regulators in plants that play pivotal roles in their biological activities. Methyl jasmonate (MJ) is very effective at inducing the myelomonocytic differentiation of human myeloid leukemia HL-60 cells. We examined the gene expression profiles associated with exposure to MJ using cDNA microarrays, and compared the results with those obtained with other inducers of differentiation, such as all-trans retinoic acid (ATRA), 1a,25-dihydroxyvitamin D 3 (VD 3 ), isopentenyladenine (IPA) and cotylenin A (CN-A). Many genes were upregulated, and only a small fraction was downregulated, upon exposure to the inducers. MJ, IPA and CN-A, but not ATRA or VD 3 , immediately induced the expression of mRNA for the calciumbinding protein S100P. The gene expression profile induced by MJ resembled that induced by IPA, suggesting that these inducers share many common signal transduction systems for inducing the differentiation of leukemia cells. Methyl 4,5-didehydrojasmonate was about 30 times more potent than MJ and the natural form of the stereoisomer was more effective than the unnatural isomer. It significantly stimulated both the functional and morphological differentiation of leukemia cells that had been freshly isolated from patients with hematological malignancies. Jasmonate derivatives may be promising therapeutic agents for differentiation therapy of leukemia.
Introduction
Jasmonic acid and its methyl ester, methyl jasmonate (MJ), are fatty acid-derived cyclopentanones in plants that play major roles in defense against insects and disease. 1, 2 The widespread occurrence of jasmonates (JAs) in plants and their capacity to regulate processes in insects support the notion that JAs exert some biological action on higher animal cells, including human cells. Structurally and biosynthetically, JAs belong to a family of oxygenated fatty acid derivatives, which are produced through the oxidative metabolism of polyunsaturated fatty acids. JA biosynthesis in plants is analogous to eicosanoid biosynthesis in animal cells. In animals, eicosanoids are synthesized from arachidonic acid, whereas in plants linolenic acid is the major source of JAs. JAs regulate plant gene expression, including defense-related genes. However, the signaling pathways mediating the action of JAs remain largely unknown. A new family of regulators of JA signaling named JAZ, jasmonate ZIM-domain proteins, has recently been described. The discovery of JAZ repressors provides a new framework to understand JA-signaling pathways from hormonal perception to transcriptional activation. 3 Several groups have reported that JAs and their synthetic derivatives exhibit anticancer activity in vitro and in vivo. [4] [5] [6] JAs inhibit cell proliferation and induce apoptosis in various cancer cell lines. Furthermore, JAs increased the lifespan of EL-4 lymphoma-bearing mice without serious adverse effects. 4 Earlier, we reported that JAs can induce myeloid leukemia cell lines to undergo differentiation into granulocytes with some monocytic properties. 5 JAs activated mitogen-activated protein kinase in cells before causing myelomonocytic differentiation. Mitogen-activated protein kinase activation was necessary for JA-induced differentiation. One novel derivative (methyl 4, 5-didehydrojasmonate) is a particularly promising therapeutic agent for differentiation therapy of leukemia.
Myeloid leukemia cells are induced to differentiate into mature granulocytes and macrophages by various inducers. 7, 8 During the differentiation of leukemia cells, the expression of leukemia-associated genes is downregulated and many maturation-associated genes are expressed normally, as in the maturation of normal neutrophils and monocytes. Although there may be common final pathways that mediate maturation in malignant cells, the precise mode of action may vary among differentiation inducers. Our previous results indicate that the gene expression profiles associated with the exposure to isopentenyladenine (IPA) are quite different from those with all-trans retinoic acid (ATRA), although both inducers effectively induce the granulocytic differentiation of myeloid leukemia HL-60 cells, 9 suggesting that IPA-induced differentiation is regulated by transcription factors that are different from those in the differentiation induced by ATRA. In the present investigation, we examined and compared the gene expression profiles in leukemia cells treated with MJ and other differentiation inducers.
Several clinical trials have confirmed that ATRA is valuable in differentiation therapy for acute promyelocytic leukemia. 10, 11 However, ATRA has had limited success as a single agent in the treatment of other hematopoietic malignancies. 12 The further development of differentiation therapy for leukemia requires new and potent inducers. Although differentiation-inducing agents potently affect the differentiation of established cell lines, they may have only a modest differentiation-inducing activity in freshly isolated leukemic cells. 13, 14 Therefore, we sought to determine whether JAs could affect the differentiation of leukemic cells from patients with acute myeloid leukemia (AML) and other hematological malignancies to determine whether JAs could be useful for differentiation therapy against myeloid leukemia.
Materials and methods

Materials
IPA, RPMI-1640 medium, nitroblue tetrazolium (NBT) and ATRA were purchased from Sigma Chemical Co. (St Louis, MO, USA), whereas 1a, 25-dihydroxyvitamin D 3 (VD 3 ), MJ and dimethyl sulfoxide were purchased from Wako Chemicals (Osaka, Japan). Cotylenin A (CN-A) was prepared as described earlier. 14 We synthesized both enantiomers of 4,5-didehydrojasmonate (DDHJ) with more than 99.8 % purity, as described earlier (Supplementary Figure A) . [15] [16] [17] [18] Leukemia patients AML was diagnosed and classified according to the FAB criteria. Leukemic bone marrow specimens were collected at diagnosis, after all of the patients gave their written informed consent for sample collection in accordance with the institutional policy. This study was approved by the Institutional Review Board at Shimane University. The clinical profiles are shown in Table 1 .
Cells and cell culture
The HL-60 cell line, derived from an AML patient, is maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and 80 mg/ml gentamicin at 37 1C in a humidified atmosphere of 5% CO 2 in air. Heparinized bone marrow aspirations were diluted with RPMI-1640 medium supplemented with 10% fetal bovine serum, overlaid on 15 ml of Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden) and centrifuged at 500 g for 30 min. Only specimens that contained at least 70% leukemia cells were studied. The mononuclear cells were washed two times, and suspended in RPMI-1640 medium supplemented with 10% fetal bovine serum, plated in culture dishes at 5-12 Â 10 5 cells/ml and incubated at 37 1C in a humidified atmosphere of 5% CO 2 in air.
Assay of cell growth and properties of differentiated cells
Suspensions of cells (5 Â 10 4 cells/ml) in 2 ml of culture medium were incubated with or without the test compounds in multidishes (Costar, Cambridge, MA, USA). Cell numbers were counted in a Model ZM Coulter Counter (Coulter Electronics, Luton, UK). Superoxide-generating oxidase was determined by the ability of the cells to reduce NBT upon exposure to 12-Otetradecanoyl phorbol-13-acetate. Formazan deposits were solubilized in dimethyl sulfoxide, and the absorption of the formazan solution at 560 nm/10 7 cells was measured in a spectrophotometer. 5 Morphological changes were examined in cell smears stained with May-Grü nwald-Giemsa solution. Surface expression of myelomonocytic antigens was determined by monoclonal antibody labeling and flow cytometry using a FACSCAN (Becton Dickinson, Mountain View, CA, USA), as described earlier. 5 
cDNA microarray analysis
Total RNA was isolated from HL-60 cells treated with or without inducers for 4, 12 and 24 h using Isogen (Nippon Gene, Toyama, Japan). Poly(A) þ RNA was reverse-transcribed with the concomitant incorporation of Cy3-and Cy5-labeled nucleotides. The labeled probes were hybridized with a cDNA microarray representing about 1000 different human genes specified for human cancer (TaKaRa Bio Inc., Tokyo), and their fluorescent intensities were scanned according to the protocol standardized by TaKaRa Bio Inc. 9 Twelve housekeeping genes were spotted onto each slide and used for signal normalization. The genes were screened by analyzing the differences in expression profiles between two genes. All analyses were performed according to the instructions of TaKaRa Bio Inc.
Gene expression analysis by RT-PCR
Total RNA was extracted using Isogen (Nippon Gene, Toyama, Japan) according to the manufacturer's instructions. Total RNA (1 mg) from leukemia cells was converted to first-strand cDNA primed with random hexamer in a Differentiation of leukemia cells by jasmonates H Tsumura et al reaction volume of 20 ml using an RNA PCR kit (TaKaRa Bio), and 4 ml of this reaction was used as a template in the polymerase chain reaction. The oligonucleotides used in PCR amplification were as follows: sense strand, 5 0 -AATCTAGC ACCATGACGGAA-3 0 ; antisense strand, 5 0 -CAACAAACACTT TTGGGAAG-3 0 for S100P. PCR consisted of 25 cycles for S100P and 18 cycles for GAPDH, with denaturing at 94 1C for 30 s, annealing at 60 1C for 30 s and extension at 72 1C for 1.5 min. 9 The quantitative RT-PCR was performed using an ABI PRISM 7000 Real-Time PCR System (Applied Biosystems Japan, Tokyo, Japan) according to the manufacturer's instructions. 
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Statistical evaluation
Statistical analyses were performed using an unpaired two-tailed Student's t-test.
Results
cDNA microarray analysis of HL-60 cells treated with MJ and other inducers
ATRA and VD 3 effectively induce the granulocytic and monocytic differentiation of human myeloid leukemia HL-60 cells, respectively. MJ induces both the granulocytic and monocytic differentiation of these cells. This was confirmed by the expression profiles of several differentiation antigens of HL-60 cells treated with MJ, ATRA, or VD 3 . 5,9 IPA is a potent cytokinin and also a potent inducer of the differentiation of human myeloid leukemia cells. 19 CN-A, which has cytokininlike activities and which was isolated as a plant growth regulator, is also a potent inducer. 14, 20 When HL-60 cells were cultured with 0.15 mM MJ, 25 mg/ml of IPA, 10 mg/ml of CN-A, 400 nM ATRA or 24 nM VD 3 for 3 days, NBT reduction was induced at the same levels (1.12-1.35 A 560 /10 7 cells), suggesting that these treatments similarly induce the differentiation of HL-60 cells. Three individual preparations were independently subjected to hybridization. A good correlation was observed among the duplicate spots, and the net ratios for the housekeeping genes were between 0.89 and 1.1. Genes with a treatment/control ratio 42 in all three experiments were considered to be significantly upregulated and those with a treatment/control ratio o0.5 were considered to be significantly downregulated. Changes in gene expression of HL-60 cells treated with MJ, IPA, CN-A, ATRA or VD 3 for 24 h are shown in Table 2 . All of the inducers significantly upregulated the expression of genes for tumor necrosis factor-a-induced protein 1 and amyloid b (A4) precursor protein. The gene for the calciumbinding protein S100P was the most upregulated gene in cells treated with MJ, IPA and CN-A, whereas ATRA and VD 3 did not significantly affect the expression of this gene. Similar changes were also observed in the expression of activating transcription factor 3 and Clk-associating RS-cyclophilin mRNAs. VD 3 greatly induced the expression of the arachidonate 5-lipoxygenase and prostaglandin-endoperoxide synthase 1 genes, whereas MJ and IPA did not significantly affect the expression of these genes. The expression of five genes was significantly upregulated by both MJ and IPA, but not by the other inducers. Table 2 shows that only three genes were differentially regulated by MJ and IPA, indicating that the gene expression profile regulated by MJ is similar to that of IPA. IPA hardly induces CD14 monocytic antigen or a-naphthyl acetate esterase activity of HL-60 cells, and stimulates morphological differentiation into granulocytes. 19, 20 On the other hand, MJ induces CD14 expression and monocyte-specific esterase activity. 5 MJ and IPA upregulated the expression of the regulator of G-protein signaling-16 (RGS16) gene, whereas ATRA significantly downregulated the expression of this gene. When the cells were treated with these inducers for 24 h, several genes were downregulated (data not shown). Expression of the gene for non-receptor type 3 protein tyrosine phosphatase was greatly reduced by all of the inducers 
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H Tsumura et al tested, although the amounts of RNA in the treated cells were below reliable levels. Transcription factor Dp-2 was also consistently downregulated by these inducers, even with treatment for 12 h (data not shown). Vimentin was downregulated by IPA, ATRA and VD 3 , but not by MJ or CN-A. Although no gene was specifically upregulated by MJ, the expression of carboxypeptidase A3 mRNA was consistently and specifically downregulated by MJ.
Regulation of S100P gene expression
The time course of the expression of S100P mRNA revealed that MJ rapidly induced the expression of this gene in HL-60 cells (Figure 1a) , suggesting that the rapid induction of the expression of this gene is involved in the induction of differentiation induced by MJ, as in that with IPA and CN-A. 9 The changes were also observed in cells that had been treated for 4 h (Figure 1a) .
To confirm the results from the cDNA microarray analysis, the expression of S100P was examined by quantitative RT-PCR analysis. When HL-60 cells were treated with MJ for 24 h, the accumulation of S100P transcript was greatly induced. The upregulation was more prominent than with induction by IPA or CN-A (Figure 1b) . On the other hand, treatment with ATRA or VD 3 did not significantly affect the expression of mRNA (Figures 1a and b) . The upregulation of S100P gene expression by MJ was also observed in other myeloid leukemia cells such as NB4, THP-1 and U937 cells, suggesting that the upregulation is not limited to HL-60 cells (data not shown).
Effects of MJ derivatives on the growth and differentiation of leukemia cells
The fragnance of the natural form of methyl 4,5-didehydrojasmonate (DDHJ) was superior to that of unnatural enantoimer and the racemate. 18 These results suggest that a specific receptor 
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for natural DDHJ is involved in the biological action. Previously, we found that DDHJ (Supplementary Figure A) was about 30-times more potent than MJ on a molar basis. 5 As the compound was tested as a racemate, that is, both the naturally occurring ( þ )-DDHJ and the unnatural (À)-enantiomer, we examined the difference in activity of these isomers on the growth and differentiation of leukemia cells. Figure 2 shows that DDHJ is more potent than unnatural DDHJ at inhibiting cell growth and inducing NBT reduction in HL-60 cells. The differential effects of these isomers were confirmed by morphologic changes and the expression of cell-surface antigens (Figure 2d) .
Leukemia cells from patients with hematological malignancies (Table 1) were freshly isolated and incubated with various concentrations of the JAs for 7 days. Treated cultures with a viability of more than 70% were evaluated. Upon treatment with DDHJ for 7 days, although the malignant cells did not grow, most of the cells were viable, suggesting that the effect of the JA is cytostatic. We analyzed NBT reduction, non-specific esterase activity, differentiation-associated antigens such as CD11b and CD14, and morphological changes. Untreated leukemia cells from an AML-M5b patient (case 4) were non-adherent and round (Figure 3a) . When the cells were cultured with 10 mM DDHJ for 2 days, more than 50% of the cells adhered to culture dishes and many cells spread over the dishes (Figure 3b ). On the other hand, the cells were hardly affected by 10 mM unnatural DDHJ (Figure 3c) . The leukemia cells were incubated with 30 mM of the stereoisomers for 7 days. Morphological examinations revealed that large azurophilic granules, which are typical of promyelocytes, were decreased in the DDHJ-treated cells and monocytes and macrophages were significantly induced by DDHJ (Figure 3e ), but not by unnatural DDHJ. DDHJ, but not unnatural DDHJ, significantly induced NBT reduction in the cells (Figure 3f ). When several differentiation-associated antigens were examined, CD14 expression was significantly induced by DDHJ, whereas the effects of unnatural DDHJ were less potent (Figure 3j) . Similar results were observed in the other cases. After leukemia cells in CML in blast crisis (case 1) were cultured for 7 days, DDHJ concentration dependently induced NBT reduction and cell-surface antigens (Figures 4a and b) . Similar results were obtained in the other cases (Figures 4c and d) . Although leukemia cells from AML-M5b patients (cases 4-6) were induced to undergo significant morphological differentiation by DDHJ, those from patients with other hematological malignancies were scarcely induced to undergo morphological changes by DDHJ. However, the expression of CD11b and CD14 was significantly enhanced by DDHJ in all of the leukemia cells tested in the present study. Although the enhancing effects of DDHJ on CD14 expression were similar to those of VD 3 in most cases, leukemia cells in case 1 (CML-BC) and case 6 (AML-M5b) were more sensitive to DDHJ than VD 3 (Figures 5a and d) . This is consistent with the 
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Discussion
Several differentiation inducers can induce HL-60 cells to differentiate into granulocytes and macrophages, but the gene expression profiles are quite different. Expression of the RGS16 gene was significantly enhanced by MJ and IPA, whereas ATRA significantly suppressed this gene expression. On the other hand, RAB31 mRNA was the most upregulated among the genes in cells treated with ATRA, but was not significantly affected by MJ or IPA (Table 2 ). Our previous results showed that IPA and CN-A preferentially upregulated S100P at the early stages of differentiation. 9 IPA-induced differentiation of HL-60 cells was suppressed by treatment with antisense oligonucleotides against S100P, suggesting that S100P plays an important role in cell differentiation. 9 The present results indicate that MJ also effectively induces S100P mRNA (Supplementary Table A) and the general gene profile is similar to that of IPA, suggesting that MJ-and IPA-induced differentiation share a similar mode of action. Interestingly, these inducers are known to regulate plant growth. 5, 19 Further research will be needed to better understand the importance of S100P in differentiation. Gene expression profile induced by natural DDHJ was essentially same to that induced by MJ (data not shown). The expression of S100P mRNA induced by DDHJ was almost same to that induced by MJ and natural DDHJ effectively induced expression of S100P mRNA whereas unnatural DDHJ did not (Supplementary Figure B) .
The precise mechanism of JA action, including the target molecules, is still unknown. A recent report showed that JAs bind directly to hexokinase and detach it from the mitochondria. 21 Interference with hexokinase and voltage-dependent anion channel interaction may lead to apoptosis. MJ-induced apoptosis and detachment of hexokinase require a high concentration of MJ (more than 3 mM). 21 On the other hand, the differentiation of leukemia cells can be significantly induced by 0.3 mM MJ. 5 These results suggest that different target molecules are involved in the JA-induced differentiation of leukemia cells. The present results which show that the natural form of DDHJ is more potent than the unnatural enantiomer in inducing differentiation of leukemia cells suggest the presence of a specific receptor(s) for DDHJ in differentiation-inducing signal transduction pathway. In plants, JAZ proteins repress JA signaling and are targeted by the E3-ubiquitin ligase SCF(COI1) for proteasome degradation in response to JA. Elimination of JAZ repressors then frees the MYC2 transcription factor to stimulate JA-dependent gene expression. Hormone binding depends on a functional COI1 protein suggesting that COI1 is the JA receptor. 3 Further research will be needed to better understand the receptor for JAs in leukemia cells.
JA and its analogs are used as flavors in foods and cosmetics, suggesting that these compounds are quite safe and clinically useful. MJ at 3 mM induced the perturbation of mitochondria in hepatoma and leukemia cells, whereas mitochondria from quiescent and mitogenically stimulated normal human peripheral blood lymphocytes were not affected by MJ, suggesting that JAs Differentiation of leukemia cells by jasmonates H Tsumura et al are preferentially cytotoxic toward malignant cells. 22 Flescher and his co-workers indicated that MJ and its analogs exhibit anticancer activity in vivo, as well as in vitro. 4, 6, [21] [22] [23] MJ was therapeutically effective in an animal model of lymphoma, 3 and its analog significantly suppressed the metastasis of murine melanoma, 23 which suggests that these compounds are clinically useful.
Our final goal is to perform clinical trials of JA derivatives for the differentiation therapy of hematopoietic malignancies. The findings obtained using human leukemia cell lines do not completely reflect the situation in patients with acute leukemia. The present results indicate that the JA analog DDHJ morphologically and functionally induces the differentiation of leukemia cells in primary culture. DDHJ alone effectively induced morphological differentiation in AML-M5b cells in primary culture. Although DDHJ can significantly affect the expression of functional markers of differentiation in other types of leukemia cells, the morphological changes induced by DDHJ alone were modest. In some cases, however, the leukemia cells were more sensitive to DDHJ than ATRA or VD 3 with regard to induction of the expression of several CD antigens. Our previous and present results indicate that introduction of the double bond at the 4,5-position greatly enhances the differentiation-inducing activity of MJ and the natural isomer is more potent. Reischer et al. 23 synthesized a series of halogenated JA derivatives and selected a tetrabromo derivative of MJ as a potent drug. These results suggest that chemical modification of the JA molecule may yield highly potent inducers of the differentiation of leukemia cells. Alternatively, a suitable combination of JA and other differentiation inducers may provide an effective therapy for leukemia, as combined treatment with JA and other inducers shows synergism for the induction of differentiation, so that their doses can be reduced. MJ and its analogs synergistically enhanced growth inhibition and differentiation in leukemia cells in combination with suboptimal concentrations of VD 3 : the effective concentration of VD 3 was reduced to the order of 0.1 nM. Therefore, the combination of VD 3 and JAs may be useful in the treatment of some hematopoietic malignancies. JAs are used as flavors in foods and cosmetics, and exhibit selective cytotoxicity towards leukemia cells while sparing normal blood lymphocytes. These results suggest that JAs are novel and promising drugs for the treatment of leukemia.
